

May 11, 2022

Sodium Acetate Injection, USP
Supply Update

Dear Valued Customer,

Fresenius Kabi Canada is pleased to advise that our remaining inventory of **Sodium Acetate Injection, USP 4 mEq/mL Maxivial® 100 mL** will be released and available across distribution centres by **May 16, 2022**. Please refer to our recent Healthcare Professional Communication “**Important Safety Information Sodium Acetate Injection, USP - Potential for the Presence of Particulate Matter**” dated May 6, 2022 for important guidance relating to use of this product (<https://www.fresenius-kabi.com/en-ca/documents/HC-approved-HPRC-Sodium-Acetate-Injection-UPDATE-EN-050622.pdf>)

Sodium Acetate Injection, USP 4 mEq/mL Maxivial® 100 mL will remain on allocation from **May to July**. **Contract customers will be allocated 100% of 100 mL demand plus 100% of 50 mL demand on a mL per mL basis (2 vials of 50 mL = 1 vial of 100 mL)**. It is anticipated that all remaining inventory will be depleted and we will be on backorder in August. Long term supply status is currently unknown; however, we assure you we are working diligently with our plants for resolution and updates can be expected in the weeks ahead. We strongly encourage all customers to use prudent conservation measures to extend the supply as long as possible.

DIN	Fresenius Kabi Product Code	MDP Product Code	Product Description	Supply Status May - July	Supply Status August
02139529	C3250	922833	Sodium Acetate Injection, USP 4 mEq/mL SD Vial 50 mL	Backorder	Backorder Estimated Availability Date: TBD
02139529	C32B1	922821	Sodium Acetate Injection, USP 4 mEq/mL Maxivial® 100 mL	Available May 16, 2022 Allocations to cover 100% of 100mL demand plus 100% of 50mL demand on a mL:mL basis (2 vials of 50 mL = 1 vial of 100 mL)	Backorder Estimated Availability Date: TBD

We recognize the difficulties and inconvenience that you may encounter as a result of our supply situation, and we thank you for your patience and understanding in this matter.

If you have any questions or concerns, please do not hesitate to contact customer service at (877) 821-7724.

Sincerely,



George Shamsoun
Associate Director, Marketing – IV Drugs
george.shamsoun@fresenius-kabi.com